PHARMACOLOGIE CLINIQUE

Ahlskog JE, Uitti RJ. Rasagiline, Parkinson neuroprotection, and delayed-start trials. Neurology 2010 ; 74 : 1151.

Barone P, Poewe W , S Albrecht S, Debieuvre C, Massey D, Rascol , Tolosa E, Weintraub D. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease : a randomised double-blind, placebo controlled trial. Lancet Neurol 2010 ; 9 : 573-580.

Bronzova J, Sampaio C, Hauser R, Lang A, Rascol O, Theeuwes A, Van de Witte S, Van Scharrenburg G, for the Bruegel Study Group. Double-blind, study of pardoprunox, a new partial dopamine agonist, in early Parkinson’s disease. Mov Disord 2010 ; 25 : 738-746.

Causse M, Sénard JM, Démonet JF, Pastor J. Monitoring cognitive and emotional processes through pupil and cardiac response during dynamic versus logical task. Appl Psychophysiol Biofeedback. 2010 ; 35(2):115-23.

Colosimo C, Martinez-Martin P, Fabbrini G, Hauser RA, Merello M, Miyasaki J, Poewe W, Sampaio C, Rascol O, Stebbins GT, Schrag A, Goetz CG. Task force report on scales to assess dyskinesia in Parkinson’s disease : critique and recommendations. Mov Dis 2010. 25 : 1131-1142.

Debs R, Cochen De Cock V, Nègre-Pagès L, Aristin M, Senard A, Rascol O, on behalf of the DoPaMiP Study Group. Thought disorders among non-demented outpatients with Parkinson’s disease : prevalence and associated factors. J Neural Transmission. 2010 ;10:1183-8.

Degris E, Delpierre C, Sommet A, Sire S, Lassoued S, Aquilina C, Marchou B, Massip P, Obadia M, Marion-Latard F, Bonnet E, Bernard J. Longitudinal study of body composition of 101 HIV men with lipodistrophy : dual-energy X-ray criteria for lipodistrophy evolution. J Clin Densitom 2010, 13, 237-44.

Dellapina E, Gerdelat-Mas A, Ory-Magne F, Pourcel L, Galitzky M, Calvas F, Simonetta-Moreau M, Thalamas C, Payoux P and Brefel-Courbon C. Apomorphine effect on pain threshold in Parkinson’s disease : A clinical and positron emission tomography study. Mov Disord, 2010.

Despas F, Pathak A, Berry M, Cagnac R, Massabuau P, Liozon E, Galinier M, Sénard JM. DBH deficiency in an elderly patient : efficacy and safety of chronic droxidopa, Clin Auton Res. 2010 Jan 9.

Despas F, Guerriero E, Galinier M, Sénard JM, Pathak A. Limited prognostic value of cardiac metaiodobenzylguanidine in patient with advanced heart failure, J Heart Lung Transplant. 2010 May ;29(5):591-2.

Despas F, Trouillet C, Franchitto N, Galinier M, Sénard JM, Pathak A. Levosimedan improves hemodynamics functions without sympathetic activation in severe heart failure patients : direct evidence from sympathetic neural recording, Acute Card Care. 2010 Mar ;12(1):25-30.

Eggert K, Squillacote, Barone P, Dodel R, Katzenschlager R, Emre M, Lees AJ, Rascol O, Poewe W, Tolosa E, Trenkwalder C, Onofrj M, Stocchi F, Nappi G, Kostic V, Potic J, Ruzicka E, Oertel W. Safety and efficacy of perampanel in advanced Parkinson’s disease : a renadomized, placebo-controlled study. Mov Dis. 2010.

Evangelou E, Maraganore DM, Annesi G, Brighina L, Brice A, Elbaz A, Ferrarese C, Hadjigeorgiou GM, Krueger R, Lambert JC, Lesage S, Markopoulou K, Mellick GD, Meeus B, Pedersen NL, Quattrone A, Van Broeckhoven C, Sharma M, Silburn PA, Tan EK, Wirdefeldt K, Ioannidis JP. Genetic Epidemiology of Parkinson’s Disease (GEOPD) Consortium. Non-replication of association for six polymorphisms from meta-analysis of genome-wide association studies of Parkinson’s disease : large-scale collaborative study. Am J Med Genet B Neuropsychiatr Genet. 2010 ; 153B(1) : 220-8.

Ferreira JJ, Neutel D, Mestre T, Coelho M, Rosa MM, Rascol O, Sampaio C. Skin cancer and Parkinson’s disease. Mov Dis 2010, 25, 139-148.

Foussal C, Lairez O, Calise D, Pathak A, Guilbeau-Frugier C, Valet P, Parini A, Kunduzova O. Activation of catalase by apelin prevents oxidative stress-linked cardiac hypertrophy. FEBS Lett. 2010 ; 584(11):2363-70. Epub 2010 Apr 14.

Friedman JH, Alves G, Hagell P, Marinus J, Marsh L, Martinez-Martin P, Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins G, Schrag A. Fatigue rating scales crititque and recommendations by the movement disorders society task force on rating scales for Parkinson’s disease. Mov Dis. 2010. 25 : 805-822.

Ferreira JJ, Rascol O, Poewe W, Sampaio C, Rocha JF, Nunes T, Almeida L, Soares-da-Silva P, on behalf of the BIA-3202-202 Study Investigators. A double-blind, randomized, placebo and active-controlled study of nebicapone for the treatment of motror fluctuations in Parkinson’s disease. CNS Neuroscience & Therapeutics 2010 (in press).

Franchitto N, Despas F, Labrunée M, Boveda S, Galinier M, Sénard JM, Pathak A. Tonic chemoreflex activation contributes to increased sympathetic nerve activity in heart failure-related anemia, Hypertension 2010 Apr ;55(4):1012-7.

Hogl B, Arnulf I, Comella C, Ferreira JJ, Iranzo A, Tilley B, Trenkwalder C and the Steering Committee Poewe W, Rascol O, Sampaio C, Stebbins GT and Goetz CG. Scales to assess sleep impairment in Parkinson’s disease : critique and recommendations. Mov Disord 2010 ; 25 : 2704-2716

Hauser RA, Schapira AHV, Rascol O, Barone P, Mizuno Y, Salin L, Haaksma M, Juhel N, Poewe W. Randomized, double-Blind, multi-center evaluation of pramipexole extended-release (ER) once daily in early Parkinson’s disease. Mov Disord. 2010 ;25:2542-9..

Koppo K, Larrouy D, Marques MA, Berlan M, Bazjova M, Polak J, Van de Voorde J, Bulow J, Lafontan M, Crampes F, Langin D, Stitch V, de Glisezinski I. Lipid mobilization in subcutaneous adipose tissue during exercise in lean and obese humans. Roles of insulin and natriuretic peptides. Am J Physiol Endocrinol Metab. 2010 ;299:E258-65.

Lesage S, Patin E, Condroyer C, Leutenegger AL, Lohmann E, Giladi N, Bar-Shira A, Belarbi S, Hecham N, Pollak P, Ouvrard-Hernandez AM, Bardien S, Carr J, Benhassine T, Tomiyama H, Pirkevi C, Hamadouche T, Cazeneuve C, Basak AN, Hattori N, Dürr A, Tazir M, Orr-Urtreger A, Quintana-Murci L, Brice A. French Parkinson’s Disease Genetics Study Group. Parkinson’s disease-related LRRK2 G2019S mutation results from independent mutational events in humans. Hum Mol Genet. 2010 ; 19 :1998-2004.

Lesage S, Condroyer C, Lohman E, Troiano A, Tison F, Viallet F, Damier P, Tranchant C, Vidhaillet M, Ouvrard-Hernandez AM, Dürr A, Brice A. French Parkinson’s Disease Genetics Study Group (FPDGSG). Follow-up study of the GIGYF2 gene in French families with Parkinson’s disease. Neurobiol Aging. 2010 ; 31 : 1069-71.

Nègre-Pagès L, Grandjean H, Lapeyre-Mestre M, Montastruc Jl, Fourrier A, Lépine JP, Rascol O on behalf DOPAMIP study Group. Anxious and depressive symptoms in Parkinson’s Disease : the french cross-sectionnal DOPAMIP study. Mov Dis 2010, 25 ; 157-166.

Olanov CW, Rascol O. The delayed-start study in Parkinson disease : can’t satisfy everyone. Neurology 2010. 74, 1149-1150.

Olanov CW, Rascol O. Commentary published today : Rasagiline in Parkinson’s disease. The authors reply. N Eng J of Med, 2010, 362, 7, 658-659.

Paris A, C. Brandt, C. Cornu, P. Maison, C. Thalamas and J. L. Cracowski. Informed consent documents improvement does not increase patients comprehension in biomedical research. Br J Clin Pharmacol, 2010, 69, 3, 231-237.

Pathak A, Berdeaux A, Mulder P, Thuillez C. Ivabradine dans la maladie coronaire : pharmacologie expérimentale et clinique. Thérapie 2010, 65, 483-489.

Pavy-Le Traon A, Fontaine S, Tap G, Guidolin B, Senard JM and Hanaire H. Cardiovascular autonomic neuropathy and other complications in type 1 diabetes. Clin Auton Res, 2010, 20, 3, 153-60.

Payoux P, Brefel-Courbon C, Ory-Magne F, Regragui W, Thalamas C, Balduyck S, Durif F, Azulay JP, Tison F, Blin O, Esquerre JP, Rascol O. Motor activation in multiple system atrophy and Parkinson’s disease : a PET study. Neurology 2010 (in press).

Péran P, Cherubini A, Assogna F, Piras F, Quattrocchi C, Peppe A, Celsis P, Rascol O, Démonet JF, Stefani A, Pierantozzi M, Pontieri F, Caltagirone C, Spalletta G, Sabatini U. Nigrostriatal signature from MRI markers in Parkinson disease. Brain 2010 ;133:3423-33.

Perez-Lloret S, Rascol O. Dopamine agonists for the treatment of early or advanced Parkinson’s disease. CNS Drugs. 2010 ;24:941-68.

Perez-Lloret S, Rascol O. Rotigotine for the treatment of Advanced Parkinson’s disease. European Neurological Review 2010 ; 4 : 24-28.

Perez Lloret S, Rascol O. Pramipexole extended-release (once-daily formulation) for the treatment of Parkinson’s disease. Exp Opin Pharmacother. 2010 ; 11 : 2221-2230.

Pillard F, Van Wymelbeke V, Garrigue E, Moro C, Crampes F, Guilland JC, Berlan M, De Glisezinski I, Harant I, Rivière D, Brondel L. Lipid oxidation in overweight men after exercise and food intake. Metabolims Clinical and experimental 2010, 267-274.

Rascol O, Azulay JP, Blin O, Bonnet AM, Brefel-Courbons C, Césaro P, Damier P, Debilly B, Durif F, Galitzky M, Grouin JM, Pennaforte S, Villafane G, Yaici S, Agid Y. orodispersible sublingual prirbedil to abort OFF episodes : a single dose placebo-controlled, randomized, double-blinb, cross-over study. Mov Dis 2010, 3, 368-376.

Rascol O, Barone P, Hauser RA, Mizuno Y, Poewe W, Schapira AHV, Salin L, Sohr M, Debieuvre C, for the Pramipexole Switch Study Group. Efficacy, safety, and tolerability of overnight switching from immediate to once daily extended-release pramipexole in early Parkinson’s disease. Mov Disord. 2010 ;25:2326-32.

Rascol O. L’UPDRS est "morte", vive la MDS-UPDRS. A nous d’en valider la traduction française ! Rev. Neurol. 2010 ; 166, 5-6.

Schapira AHV, Albrecht S, Barone P, Comella CL, McDermott M, Mizuno Y, Poewe W, Rascol O, Marek K. Rationale for delayed-start study of pramipexole in Parkinson’s disease : the PROUD study. Mov Disord. 2010 ;25:1627-32.

Senard JM, Pathak A. Neurogenic orthostatic hypotension of Parkinson’s disease : what exploration for what treatment ? Rev Neurol. 2010, 166, 779-784.

Stocchi F, Rascol O , Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow W. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson’s disease. The STRIDE-PD Study. Ann Neurol 2010 ; 68 : 18-27.

Williams A, Gill S, Varma T, Jenkinson C, Quinn N, Mitchell R, Scott R, Ives N, Rick C, Daniels J, Patel S, Wheatley K, on behalf of the PD SURG Collaborative Group. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson’s disease (PD SURG trial) : a randomised, open-label trial. Lancet Neurol 2010 ; 9 : 581-591.

Bounes V, Barthélémy R, Diez O, Charpentier S, Montastruc JL, Bagheri H. Sulfentanil is not superior to morphine for the treatment of acute traumatic pain in an emergency setting : a randomized, double-blind out of hospital trial. Ann Emerg Med 2010 ;56:509-16.

Wiesner S, Birkenfeld AL, Engeli S, Haufe S, Brechtel L, Wein J, Hermsdorf M, Karnahl B, Berlan M, Lafontan M, Sweep FC, Luft FC, Jordan J. Neurohumoral and metabolic response to exercise in water. Horm Metab Res 2010. 42 ; 334-9.

PHARMACOÉPIDÉMIOLOGIE, PHARMACOLOGIE SOCIALE, PHARMACOVIGILANCE, PHARMACODÉPENDANCE, ADDICTOVIGILANCE

Bagheri H. Glitazones et hépatites. Bulletin Audois d’Information de Pharmacologie. Mai 2010.

Bagheri H. Dermatomyosite et anti TNF alpha. Bulletin Audois d’Information de Pharmacologie. Novembre 2010.

Biboulet M, Lapeyre-Mestre M, Gardette V. Comparaison de la consommation de benzodiazépines selon le type d’usage de la buprénorphine dans une cohorte de nouveaux usagers. Prat Org Soins 2010, 41, 205-213.

Bismuth S, Chalvignac C, Bagheri H, Oustric S. Prescription de médicaments ASMR de niveau V chez les sujets de plus de 65 ans en soins primaire ambulatoires. La Revue du Praticien 2010, 60, 1.

Bœuf-Cazou O, Niezborala M, Marquie JC, Lapeyre-Mestre M. Factors associated with psychoactive drug initiation in a sample of workers in France : results of the VISAT cohort study. Pharmacoepidemiol Drug Saf 2010, 19 : 296-305.

Escourrou B, Bouville B, Bismuth M, Durrieu G, Oustric S. Self-medication in children by parents : a real risk ? A cross sectional descriptive study. Rev Prat 2010, 20, 2734.

Frauger E, Pauly V, Pradel V, Rouby F, Arditti J, Thirion X, Lapeyre-Mestre M. Micallef J. Evidence of clonazepam abuse liability : results of the tools developed by the french centers for evaluation and information on pharmacodependance (CEIP) network. Fundam Clin Pharmacol 2010 PMID 21077937.

Fuzier R. Une surveillance accrue des effets indésirables. Plateaux Techniques actualités 2010. 45. 30.

Julians-Minou G, Bruch S, Peyre N, Sudérie G, Lapeyre-Mestre M, Roussin A. La buprénorphine pour le traitement de la dépendance aux opiacés : une étude sur la substitution par les génériques menée en pharmacie d’officine. Thérapie 2010, 65 : 241-247.

Orriols L, Delorme B, Gadegbeku B, Tricotel A, Contrand B, Laumon B, Salmi LR, Lagarde E, on behalf of the CESIR research group. Prescription medicines and the risk of road traffic crashes : a french registry-based study. Plos Med 2010, 7, e1000366.

Pradel V, Delga C, Rouby F, Micallef J, Lapeyre-Mestre M. Assessment of abuse potential of benzodiazepines from a prescription database using doctor shopping as an indicator. CNS Drugs 2010, 24 : 611-620.

Bagheri H, Montastruc JL, Lavezzi O. Plavix° (clopidogrel) et ses génériques : parfait exemple de confusion règlementaire, au profit de qui ? Rev Prescrire 2010, 30, 553.

Boudal P, Sommet A, Bagheri H, Pathak A , Montastruc JL. Bleedings induced by oral anticoagulants : o study of adverse drug reactions reported to Midi-Pyrénées PharmacoVigilance Centre between 2003 and 2006. Thérapie 2010, 65, 567-569.

Caillet C, Durrieu G, Jacquet A, Faucher A, Ouaret S, Perrault-Pochat MC, Kreft-Jais C, Castot A, Montastruc JL. Safety surveillance on influenza A(H1N1)v monovalent vaccines during the 2009-2010 mass vaccination campaign in France. Eur J Clin Pharmacol 2010. Décembre 2010.

Chebane L, Tavassoli N, Bagheri H, Montastruc JL et le réseau des Centres Régionaux de Pharmacovigilance Français. Hyperglycémies d’origine médicamenteuse : étude dans la Base Nationale Française de PharmacoVigilance (BNPV). Thérapie 2010, 65, 447-458.

Droz-Perroteau C, Dureau-Purnin C, Vespignani H, Marchal C, Blin P, Blazejewski S, Pollet C, Jové J, Robinson P, Moore N, Fourrier-Réglat A, and the scientific committee members of the EULEV Study group : Vespignani H, Marchal C, Alpérovitch A, Bénichou J, Jager A, Lavernhe G, Mann M, Montastruc JL, Pédespan JM. The EULEV cohort study : rates of and factos associated with continuation of levetiracetam after 1 year. Br J Clin Pharmacol 2010, 71, 121-127.

Dupouy J, Petureau F, Montastruc JL, Oustric S, Degano B. Une cause rare de cyanose : sulfhémoglobinémie imputable au thiocolchicoside (Miorel°). Revue des Maladies Respiratoires 2010, 27, 80-83.

Durrieu G, Hurault C, Damase-Michel C, Montastruc JL. Perception of risk of adverse drug reactions : a 3-year follow-up of a cohort of medical students. Fundam Clin Pharmacol 2010, 24, 423-427.

Fuzier R, Serres I, Lapeyre-Mestre M, Montastruc. Pharmacovigilance des médicaments antihyperalgésiants. In compte-rendu du 52e Congrès National d’anesthésie et de réanimation. Evaluation et traitement de la douleur 2010, 1-11.

Gallini A, Degris E, Desplas M, Bourrel R, Archambaud M, Montastruc JL, Lapeyre-Mestre M, Sommet A. Influence of fluoroquinolone consumption in inpatients and outpatients on ciprofloxacin-resistant Escherichia Coli in a university hospital. J Antimicrob Chemother 2010, 65, 2650-2657.

Gardette V, Andrieu S, Lapeyre-Mestre M, Coley N, Cantet C, Ousset PJ, Grand A, Montastruc JL, Vellas B. Predictive factors of discontinuation and switch of cholinesterase inhibitors in community-dwelling patients with Alzheimer’s Disease. Drugs 2010, 24, 431-442.

Gony M, Badie K, Sommet A, Jacquot J, Baudrin D, Gauthier P, Montastruc JL, Bagheri H. Improving adverse drug reaction reporting in hospitals. Results of the French Pharmacovigilance in Midi-Pyrénées Region (PharmacoMIP) Network 2-year pilot study. Drug Saf 2010, 33, 409-416.

Lacroix I, Damase-Michel C, Montastruc JL. : Vaccin de la grippe A(H1N1)v et grossesse. In CD Rom. 22e Forum Medical de Rangueil de Toulouse. Faculté de Médecine de Rangueil.

Moulis G, Bagheri H, Saint Martory J, Bernard P, Montastruc JL. Very late relapse of dapsone-induced methaemoglobinemia. Eur J Clin Pharmacol 2010, 66, 645-646.

Moulis G, Pugnet G, Bagheri H, Courtellemont C, Huart A, Chauveau D, Pourrat J, Montastruc JL. Acquired factor VII haemophilia following influenza vaccination. Eur J Clin Pharmacol 2010, 66, 1069-1070.

Montastruc JL, Bagheri H, Damase C. Rimonabant, benfluorex, sibutramine : l’histoire se répète ! Plaidoyer pour la prise en compte des données pharmacodynamiques de base. Bulletin Audois d’Information de Pharmacologie. Mai 2010.

Montastruc JL. Le lien entre inhibiteurs de la Pompe à Protons (IPP) et pneumopathie confirmé par une méta-analyse. Bulletin Audois d’Information de Pharmacologie. Mai 2010.

Montastruc JL. Remède ou médicament ? Réflexions d’un pharmacologue. Prescrire 2010, 315, 73.

Montastruc G, Favreliere S, Sommet A, Pathak A, Lapeyre-Mestre M, Perault-Pochat MC, Montastruc JL and the French Association of regional PharmacoVigilance Centres. Drugs and dilated cardiomyopathies : a case/noncase study in the french PharmacoVigilance Database. Br J Clin Pharmacol 2010, 69, 287-294.

Montastruc JL, Durrieu G, Sommet A, Damase-Michel C, Lapeyre-Mestre M. Anticholinergics, antimuscarinics or atropinics ? About the words in pharmacology. Br JClin Pharmacol 2010, 69, 5 ; 561-562.

Montastruc JL, Danton AC, Durrieu G. Neuropathy as a potential complication of levodopa use in Parkinson’s disease : a pharmacological and pharmacovigilance point of view. Mov Dis 2010, 25, 660-661.

Montastruc JL. Réflexions après le retrait de la rosiglitazone. Bulletin Audois d’Information de Pharmacologie. novembre 2010.

Olivier P, Montastruc JL, et le réseau français des centres régionaux de pharmacovigilance. Profil d’effets indésirables des insaponifiables d’avocat et de soja. Presse Médicament 2010, 39, 211-216.

Perez-Lloret S, Bondon-Guitton E, Rascol O, Montastruc JL, and the French Association of Regional Pharmacovigilance. Adverse drug reactions to dopamine agonists : a comparative study in the French pharmacovigilance database. Mov Disord 2010, 12, 1876-1880.

Roussin A, Montastruc JL, Lapeyre-Mestre M. More about the safety of propofol. Br Med J 2010, 1.

Senard-orejo A, Durrieu G, Depiesse F, Schmitt L, Rivière D, Montastruc JL. Consommation de substances interdites chez le sportif : étude à l’Antenne Médicale de Prévention du Dopage de Midi-Pyrénées (AMPD-MP). Thérapie 2010, 65, 459-463.

Tavassoli N, Voisin S, Carrie D, Lapeyre-Mestre M, Galinier M, Montastruc JL, Pathak A. High maintenance dosage of clopidogrel is associated with a reduced risk of stent thrombosis in clopidogrel-resistant patients. American Journal Cardiovascular Drugs 2010, 10, 29-35.

Weill A, Paita W, Tuppin P, Fagot JP, Neumann A, Simon D, Ricordeau P, Montastruc JL, Allemand H. Benfluorex and valvular heart disease : a cohort study of a million people with diabetes mellitus. Pharmacoepidemiol. DrugS. 2010, 19, 1256-1262.